

## DAFTAR PUSTAKA

- Abdulqader, S. B., Almujaivel, N., Alshakweer, W., & Alzhrani, G. (2020). High-grade sphenoidal meningioma in patients with systemic lupus erythematosus: Two case reports and literature review. *Surgical Neurology International*, 11.
- Abed, S. A., Mahdi, R. S., Jabbar, A. A., Khaleel, A. M., & Hussein, S. S. (2020). Association between ki67 and PR Expression in Grades of Meningioma and its Prognosis. *Prof.(Dr) RK Sharma*, 20(4), 41110.
- Adimoolam, S., & Ford, J. M. (2003). p53 and regulation of DNA damage recognition during nucleotide excision repair. *DNA repair*, 2(9), 947-954.
- Agopiantz, M., Carnot, M., Denis, C., Martin, E., & Gauchotte, G. (2023). Hormone Receptor Expression in Meningiomas: A Systematic Review. *Cancers*, 15(3), 980.
- Aguiar, P. H., Agner, C., Simm, R., Freitas, A. B., Tsanaclis, A. M., & Plese, J. (2002). p53 Protein expression in meningiomas—a clinicopathologic study of 55 patients. *Neurosurgical review*, 25, 252-257.
- Al-Khalaf, H. H., Lach, B., Allam, A., AlKhani, A., Alrokayan, S. A., & Aboussekhra, A. (2007). The p53/p21 DNA damage-signaling pathway is defective in most meningioma cells. *Journal of Neuro-oncology*, 83, 9-15.
- Alexiou, G. A., Markoula, S., Gogou, P., & Kyritsis, A. P. (2011). Genetic and molecular alterations in meningiomas. *Clinical neurology and neurosurgery*, 113(4), 261-267.
- Almeida, L. O., Custódio, A. C., Pinto, G. R., Santos, M. J., Almeida, J. R., Clara, C. & Casartelli, C. (2009). Polymorphisms and DNA methylation of gene TP53 associated with extra-axial brain tumors. *Genet Mol Res*, 8(1), 8-18..
- Aman R, Keswani R, Ichwwan S, Ashari S, N.S. (2020) 'Evaluasi visus dan indeks proptosis pasien meningioma sphenoorbita pascaoperasi kraniektomi', 37, pp. 238–241.
- Amatya, V. J., Takeshima, Y., Sugiyama, K., Kurisu, K., Nishisaka, T., Fukuhara, T., & Inai, K. (2001). Immunohistochemical study of Ki-67 (MIB-1), p53 protein, p21WAF1, and p27KIP1 expression in benign, atypical, and anaplastic meningiomas. *Human pathology*, 32(9), 970-975.
- Assi, H. I., Hilal, L., Abu-Gheida, I., Berro, J., Sukhon, F., Skaf, G., & Najjar, M. (2020). Demographics and outcomes of meningioma patients treated at a tertiary care center in the Middle East. *Clinical Neurology and Neurosurgery*, 195, 105846.
- Apra, C., Peyre, M., & Kalamarides, M. (2018). Current treatment options for meningioma. *Expert review of neurotherapeutics*, 18(3), 241-249.
- Bakker, M. A. D., Tilborg, A. A. V., Kros, J. M., & Zwarthoff, E. C. (2001). Truncated NF2 proteins are not detected in meningiomas and schwannomas. *Neuropathology*, 21(3), 168-173.
- Baldi, I., Engelhardt, J., Bonnet, C., Bauchet, L., Berteaud, E., Grüber, A., & Loiseau, H. (2018). Epidemiology of meningiomas. *Neurochirurgie*, 64(1), 5-

14.

- Barbareschi, M., Iuzzolino, P., Pennella, A., Allegranza, A., Arrigoni, G., Dalla Palma, P., & Doglioni, C. (1992). p53 protein expression in central nervous system neoplasms. *Journal of clinical pathology*, *45*(7), 583.
- Bouillot, P., Pellissier, J. F., Devictor, B., Graziani, N., Bianco, N., Grisoli, F., & Figarella-Branger, D. (1994). Quantitative imaging of estrogen and progesterone receptors, estrogen-regulated protein, and growth fraction: immunocytochemical assays in 52 meningiomas: Correlation with clinical and morphological data. *Journal of neurosurgery*, *81*(5), 765-773.
- Battu, S., Kumar, A., Pathak, P., Purkait, S., Dhawan, L., Sharma, M. C., ... & Suri, V. (2018). Clinicopathological and molecular characteristics of pediatric meningiomas. *Neuropathology*, *38*(1), 22-33.
- Begnami, M. D., Palau, M., Rushing, E. J., Santi, M., & Quezado, M. (2007). Evaluation of NF2 gene deletion in sporadic schwannomas, meningiomas, and ependymomas by chromogenic in situ hybridization. *Human pathology*, *38*(9), 1345-1350.
- Bi, W. L., Abedalthagafi, M., Horowitz, P., Agarwalla, P. K., Mei, Y., Aizer, A. & Dunn, I. F. (2016). Genomic landscape of intracranial meningiomas. *Journal of neurosurgery*, *125*(3), 525-535.
- Boulos, P. T., Dumont, A. S., Mandell, J. W., & Jane, J. A. (2001). Meningiomas of the orbit: contemporary considerations. *Neurosurgical focus*, *10*(5), 1-10.
- Buccoliero, A. M., Castiglione, F., Degl'Innocenti, D. R., Gheri, C. F., Garbini, F., Taddei, A., & Taddei, G. L. (2007). NF2 gene expression in sporadic meningiomas: Relation to grades or histotypes real time-PCR study. *Neuropathology*, *27*(1), 36-42.
- Bukovac, A., Kafka, A., Hrašćan, R., Vladušić, T., & Pećina-Šlaus, N. (2019). Nucleotide variations of TP53 exon 4 found in intracranial meningioma and in silico prediction of their significance. *Molecular and clinical oncology*, *11*(6), 563-572.
- Butscheidt, S., Ernst, M., Rolvien, T., Hubert, J., Zustin, J., Amling, M., & Martens, T. (2019). Primary intraosseous meningioma: clinical, histological, and differential diagnostic aspects. *Journal of Neurosurgery*, *133*(2), 281-290.
- Butts, A., Syrjanen, J. A., Aakre, J., Brown, P. D., Jack, C. R., Petersen, R. & Cerhan, J. H. (2017). Epidemiologic study of risk factors for meningioma in the Mayo Clinic Study of Aging.
- Butts, C. L., Shukair, S. A., Duncan, K. M., Bowers, E., Horn, C., Belyavskaya, & Sternberg, E. M. (2007). Progesterone inhibits mature rat dendritic cells in a receptor-mediated fashion. *International immunology*, *19*(3), 287-296.
- Carvalho, G. T. C., da Silva-Martins, W. C., de Magalhães, K. C. S. F., Nunes, C. B., Soares, A. N., de Assis Tafuri, L. S., & Simões, R. T. (2020). Recurrence/regrowth in grade I meningioma: how to predict?. *Frontiers in oncology*, *10*.
- Cea-Soriano, L., Blenk, T., Wallander, M. A., & Rodríguez, L. A. G. (2012). Hormonal therapies and meningioma: is there a link?. *Cancer epidemiology*, *36*(2), 198-205.

- Chang, Z., Guo, C. L., Ahronowitz, I., Stemmer-Rachamimov, A. O., MacCollin, M., & Nunes, F. P. (2009). A role for the p53 pathway in the pathology of meningiomas with NF2 loss. *Journal of neuro-oncology*, 91, 265-270.
- Cho, H., Ha, S. Y., Park, S. H., Park, K., & Chae, Y. S. (1999). Role of p53 gene mutation in tumor aggressiveness of intracranial meningiomas. *Journal of Korean medical science*, 14(2), 199-205.
- Chow, H. Y., Dong, B., Duron, S. G., Campbell, D. A., Ong, C. C., Hoeflich, K. & Chernoff, J. (2015). Group I Paks as therapeutic targets in NF2-deficient meningioma. *Oncotarget*, 6(4), 1981.
- Chowdhury, T., Yoo, Y., Seo, Y., Dho, Y. S., Kim, S., Choi, A., ... & Lee, J. Y. (2018). Genomic analysis of synchronous intracranial meningiomas with different histological grades. *Journal of Neuro-Oncology*, 138, 41-48.
- Choy, W., Kim, W., Nagasawa, D., Stramotas, S., Yew, A., Gopen, Q., ... & Yang, I. (2011). The molecular genetics and tumor pathogenesis of meningiomas and the future directions of meningioma treatments. *Neurosurgical focus*, 30(5), E6.
- Claus, E. B., Park, P. J., Carroll, R., Chan, J., & Black, P. M. (2008). Specific genes expressed in association with progesterone receptors in meningioma. *Cancer research*, 68(1), 314-322.
- Claus, E. B., Calvocoressi, L., Bondy, M. L., Wrensch, M., Wiemels, J. L., & Schildkraut, J. M. (2013). Exogenous hormone use, reproductive factors, and risk of intracranial meningioma in females. *Journal of neurosurgery*, 118(3), 649-656.
- Commins, D. L., Atkinson, R. D., & Burnett, M. E. (2007). Review of meningioma histopathology. *Neurosurgical focus*, 23(4), E3.
- Cordera, S., Bottacchi, E., D'alessandro, G., Machado, D., De Gonda, F., & Corso, G. (2002). Epidemiology of primary intracranial tumours in NW Italy, a population based study: stable incidence in the last two decades. *Journal of neurology*, 249, 281-284.
- Cross, S. J., Linker, K. E., & Leslie, F. M. (2017). Sex- dependent effects of nicotine on the developing brain. *Journal of neuroscience research*, 95(1-2), 422-436.
- Csonka, T., Murnyák, B., Szepesi, R., Kurucz, A., Klekner, Á., & Hortobágyi, T. (2014). Poly (ADP-ribose) polymerase-1 (PARP1) and p53 labelling index correlates with tumour grade in meningiomas. *Folia Neuropathologica*, 52(2), 111-120.
- Csonka, T., Murnyák, B., Szepesi, R., Bencze, J., Bognár, L., Klekner, Á., & Hortobágyi, T. (2016). Assessment of candidate immunohistochemical prognostic markers of meningioma recurrence. *Folia Neuropathologica*, 54(2), 114-126.
- Custer, B., Longstreth, W. T., Phillips, L. E., Koepsell, T. D., & Van Belle, G. (2006). Hormonal exposures and the risk of intracranial meningioma in women: a population-based case-control study. *BMC cancer*, 6(1), 1-9.
- Dahlan, M. S. (2019). Besar Sampel Untuk Penelitian Kesehatan.
- Desai, P. B., & Patel, D. (2016). A study of meningioma in relation to age, sex, site,

- symptoms, and computerized tomography scan features. *Int J Med Sci Public Health*, 5(2), 331-334.
- Dimtsas, G. S., Georgiadi, E. C., Karakitsos, P., Vassilakopoulos, T. P., Thymara, I., Korkolopoulou, & Doussis-Anagnostopoulou, I. A. (2014). Prognostic significance of immunohistochemical expression of the angiogenic molecules vascular endothelial growth factor-A, vascular endothelial growth factor receptor-1 and vascular endothelial growth factor receptor-2 in patients with classical Hodgkin lymphoma. *Leukemia & lymphoma*, 55(3), 558-564.
- Domingues, P., González-Tablas, M., Otero, Á., Pascual, D., Ruiz, L., Miranda, D., ... & Taberner, M. D. (2015). Genetic/molecular alterations of meningiomas and the signaling pathways targeted. *Oncotarget*, 6(13), 10671
- Dustur, S., Wahyuhadi, J., Utomo, B., Parenrengi, M. A., Bajamal, A. H., & Dwiningsih, S. R. (2022). Relationship Histopathology Grading of Meningioma with the Use of Medroxyprogesterone Acetate (MPA) as A Hormonal Contraceptive. *Pharmacognosy Journal*, 14(6s).
- Edlinger, M., Strohmaier, S., Jonsson, H., Bjørge, T., Manjer, J., Borena, W. T., ... & Ulmer, H. (2012). Blood pressure and other metabolic syndrome factors and risk of brain tumour in the large population-based Me-Can cohort study. *Journal of hypertension*, 30(2), 290-296.
- Elborady, M. A., & Nazim, W. M. (2021). Spheno-orbital meningiomas: surgical techniques and results. *The Egyptian Journal of Neurology, Psychiatry and Neurosurgery*, 57, 1-9.
- Euskirchen, P. and Peyre, M. (2018) 'Management of meningioma', *Presse Medicale* [Preprint]. Available at: <https://doi.org/10.1016/j.lpm.2018.05.016>.
- Euskirchen, P., & Peyre, M. (2018). Management of meningioma. *La Presse Médicale*, 47(11-12), e245-e252.
- Fakhrjou, A., Meshkini, A., & Shadravan, S. (2012). Status of Ki-67, estrogen and progesterone receptors in various subtypes of intracranial meningiomas. *Pakistan journal of biological sciences: PJBS*, 15(11), 530-535.
- Fischer, B. R., & Brokinkel, B. (2012). Surgical Management of Skull Base Meningiomas—An Overview. *Meningiomas management and surgery. Shanghai, China: InTech*, 85-102.
- Galani, V., Lampri, E., Varouktsi, A., Alexiou, G., Mitselou, A., & Kyritsis, A. P. (2017). Genetic and epigenetic alterations in meningiomas. *Clinical neurology and neurosurgery*, 158, 119-125..
- Garcia-Ruiz, G., Flores-Espinosa, P., Preciado-Martínez, E., Bermejo-Martínez, L., Espejel-Núñez, A., Estrada-Gutierrez, & Zaga-Clavellina, V. (2015). In vitro progesterone modulation on bacterial endotoxin-induced production of IL-1 $\beta$ , TNF $\alpha$ , IL-6, IL-8, IL-10, MIP-1 $\alpha$ , and MMP-9 in pre-labor human term placenta. *Reproductive Biology and Endocrinology*, 13(1), 1-12
- Garcia, G. A., Choy, A. E., Hasso, A. N., & Minckler, D. S. (2018). Malignant orbital meningioma originating from the frontal lobe. *Ocular oncology and pathology*, 4(3), 186-190.
- Govindan, A., & Alapatt, J. P. (2023). Progesterone and Estrogen Receptors in Meningiomas—A Clinicopathological Analysis. *Journal of Cancer Research*

*Updates, 12, 10-15.*

- Goldbrunner, R., Minniti, G., Preusser, M., Jenkinson, M. D., Sallabanda, K., Houdart, E., & Weller, M. (2016). EANO guidelines for the diagnosis and treatment of meningiomas. *The Lancet Oncology, 17*(9), e383-e391..
- Grigoraş, A., Rîşcanu, L., & Amălinei, C. (2018). Meningiomas–insights into genetics and correlations with histological features. *Archive of Clinical Cases, 5*(1).
- Grunberg, S. M., Weiss, M. H., Russell, C. A., Spitz, I. M., Ahmadi, J., Sadun, A., & Sitruk-Ware, R. (2006). Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma. *Cancer investigation, 24*(8), 727-733.
- Güdük, M., Özduman, K., & Pamir, M. N. (2019). Sphenoid wing meningiomas: surgical outcomes in a series of 141 cases and proposal of a scoring system predicting extent of resection. *World neurosurgery, 125*, e48-e59.
- He, S., Pham, M. H., Pease, M., Zada, G., Giannotta, S. L., Wang, K., & Mack, W. J. (2013). A review of epigenetic and gene expression alterations associated with intracranial meningiomas. *Neurosurgical focus, 35*(6), E5.
- Ho, C. Y., Mosier, S., Safneck, J., Salomao, D. R., Miller, N. R., Eberhart, C. & Rodriguez, F. J. (2015). Genetic profiling by single-nucleotide polymorphism-based array analysis defines three distinct subtypes of orbital meningioma. *Brain Pathology, 25*(2), 193-201.
- Hosmer, D. W., Hosmer, T., Le Cessie, S., & Lemeshow, S. (1997). A comparison of goodness-of-fit tests for the logistic regression model. *Statistics in medicine, 16*(9), 965-980.
- Hortobágyi, T., Bencze, J., Varkoly, G., Kouhsari, M. C., & Klekner, Á. (2016). Meningioma recurrence. *Open Medicine, 11*(1), 168-173.
- Hsu, D. W., Pardo, F. S., Efird, J. T., Linggood, R. M., & Hedley-Whyte, E. T. (1994). Prognostic significance of proliferative indices in meningiomas. *Journal of neuropathology and experimental neurology, 53*(3), 247-255.
- Hsu, D. W., Efird, J. T., & Hedley-Whyte, E. T. (1997). Progesterone and estrogen receptors in meningiomas: prognostic considerations. *Journal of neurosurgery, 86*(1), 113-120.
- Iplikcioglu, A. C., Hatiboglu, M. A., Ozek, E., & Ozcan, D. (2014). Is progesteron receptor status really a prognostic factor for intracranial meningiomas?. *Clinical Neurology and Neurosurgery, 124*, 119-122.
- Ikeri, N. Z., Anunobi, C. C., & Bankole, O. B. (2018). Progesterone receptor expression and Ki-67 labelling index of meningiomas in the Lagos university teaching hospital. *Nigerian Postgraduate Medical Journal, 25*(1), 17-20.
- Jagannathan, J., Oskouian, R. J., Yeoh, H. K., Saulle, D., & Dumont, A. S. (2008). Molecular biology of unresectable meningiomas: implications for new treatments and review of the literature. *Skull Base, 18*(3), 173..
- Jain, A., Suri, V., Sharma, B. S., & Sharma, M. C. (2010). Mixed schwannoma with meningioma of the trigeminal nerve. *Indian Journal of Pathology and*

*Microbiology*, 53(4), 769-771.

- Jhawar, B. S., Fuchs, C. S., Colditz, G. A., & Stampfer, M. J. (2003). Sex steroid hormone exposures and risk for meningioma. *Journal of neurosurgery*, 99(5), 848-853.
- Jha, R., & Bista, P. (2020). Clinicopathological characteristics of intracranial meningiomas. *Nepal Journal of Neuroscience*, 17(2).
- Kaneko, T., Yamashima, T., Tohma, Y., Nomura, M., Imajoh- Ohmi, S., Saido, T. C., ... & Yamashita, J. (2001). Calpain- dependent proteolysis of merlin occurs by oxidative stress in meningiomas: A novel hypothesis of tumorigenesis. *Cancer: Interdisciplinary International Journal of the American Cancer Society*, 92(10), 2662-2672.
- Karamitopoulou, E., Perentes, E., Tolnay, M., & Probst, A. (1998). Prognostic significance of MIB-1, p53, and bcl-2 immunoreactivity in meningiomas. *Human pathology*, 29(2), 140-145.
- Kemenkes, R. I. (2018). Peta Jalan Penanggulangan Gangguan Penglihatan di Indonesia Tahun 2017-2030. *Jakarta: Direktorat Jenderal Pencegahan dan Pengendalian Penyakit Kementerian Kesehatan Republik Indonesia*.
- Khalid, H. (1994). Immunohistochemical study of estrogen receptor- related antigen, progesterone, and estrogen receptors in human intracranial meningiomas. *Cancer*, 74(2), 679-685.
- Kim, H., Kwak, N. J., Lee, J. Y., Choi, B. H., Lim, Y., Ko, Y. & Wang, Y. P. (2004). Merlin neutralizes the inhibitory effect of Mdm2 on p53. *Journal of Biological Chemistry*, 279(9), 7812-7818.
- Kim, M., Kim, H. J., Cho, Y. H., Kim, J. H., & Kwon, D. H. (2017). Analysis of the results of recurrent intracranial meningiomas treated with re-radiosurgery. *Clinical Neurology and Neurosurgery*, 153, 93-101..
- Korhonen, K., Salminen, T., Raitanen, J., Auvinen, A., Isola, J., & Haapasalo, H. (2006). Female predominance in meningiomas can not be explained by differences in progesterone, estrogen, or androgen receptor expression. *Journal of neuro-oncology*, 80, 1-7.
- Korhonen, K., Auvinen, A., Lyytinen, H., Ylikorkala, O., & Pukkala, E. (2012). A nationwide cohort study on the incidence of meningioma in women using postmenopausal hormone therapy in Finland. *American journal of epidemiology*, 175(4), 309-314.
- Kotipatruni, R. P., Ren, X., Thotala, D., & Jaboin, J. J. (2015). NDRG4 is a novel oncogenic protein and p53 associated regulator of apoptosis in malignant meningioma cells. *Oncotarget*, 6(19), 17594.
- Kuan, A. S., Chen, Y. T., Teng, C. J., Wang, S. J., & Chen, M. T. (2014). Risk of meningioma in patients with head injury: a nationwide population-based study. *Journal of the Chinese Medical Association*, 77(9), 457-462.
- Kumar, S., Kakkar, A., Suri, V., Kumar, A., Bhagat, U., Sharma, M. & Sarkar, C. (2014). Evaluation of 1p and 14q status, MIB-1 labeling index and progesterone receptor immunoexpression in meningiomas: Adjuncts to histopathological grading and predictors of aggressive behavior. *Neurology India*, 62(4), 376..

- Kyriakis, J. M., & Avruch, J. (2012). Mammalian MAPK signal transduction pathways activated by stress and inflammation: a 10-year update. *Physiological reviews*, 92(2), 689-737.
- Lanzafame, S., Torrissi, A., Barbagallo, G., Emmanuele, C., Alberio, N., & Albanese, V. (2000). Correlation between histological grade, MIB-1, p53, and recurrence in 69 completely resected primary intracranial meningiomas with a 6 year mean follow-up. *Pathology-Research and Practice*, 196(7), 483-488.
- Lassie, N., & Supartoto, A. (2016). Progesterone Receptor Expression in Histopathological Subtypes of Benign Orbitocranial Meningiomas. *Ophthalmologica Indonesiana*, 42(1).
- Lee, J. H., Kim, O. L., Seo, Y. B., & Choi, J. H. (2017). Prognostic factors of atypical meningioma: overall survival rate and progression free survival rate. *Journal of Korean Neurosurgical Society*, 60(6), 661-666.
- Li, P., Hao, S., Bi, Z., Zhang, J., Wu, Z., & Ren, X. (2015). Methylation of Werner syndrome protein is associated with the occurrence and development of invasive meningioma via the regulation of Myc and p53 expression. *Experimental and Therapeutic Medicine*, 10(2), 498-502.
- Li, W., Cooper, J., Karajannis, M. A., & Giancotti, F. G. (2012). Merlin: a tumour suppressor with functions at the cell cortex and in the nucleus. *EMBO reports*, 13(3), 204-215.
- Louis, D. N., Perry, A., Reifenberger, G., Von Deimling, A., Figarella-Branger, D., Cavenee, W. K., & Ellison, D. W. (2016). The 2016 World Health Organization classification of tumors of the central nervous system: a summary. *Acta neuropathologica*, 131, 803-820.
- Maiuri, F., Mariniello, G., de Divitiis, O., Esposito, F., Guadagno, E., Teodonna, G., & Del Basso De Caro, M. (2021). Progesterone receptor expression in meningiomas: pathological and prognostic implications. *Frontiers in Oncology*, 11, 611218.
- Marastoni, E., & Barresi, V. (2023). Meningioma Grading beyond Histopathology: Relevance of Epigenetic and Genetic Features to Predict Clinical Outcome. *Cancers*, 15(11), 2945.
- Marciscano, A. E., Stemmer-Rachamimov, A. O., Niemierko, A., Larvie, M., Curry, W. T., Barker, F. & Shih, H. A. (2016). Benign meningiomas (WHO Grade I) with atypical histological features: correlation of histopathological features with clinical outcomes. *Journal of neurosurgery*, 124(1), 106-114.
- Marosi, C., Hassler, M., Roessler, K., Reni, M., Sant, M., Mazza, E., & Vecht, C. (2008). Meningioma. *Critical reviews in oncology/hematology*, 67(2), 153-171.
- Menon, S., O, S., Anand, D., & Menon, G. (2020). Spheno-orbital meningiomas: optimizing visual outcome. *Journal of neurosciences in rural practice*, 11(03), 385-394.
- Mnango, L., Mwakimonga, A., Ngaiza, A. I., Yahaya, J. J., Vuhahula, E., & Mwakigonja, A. R. (2021). Expression of progesterone receptor and its association with clinicopathological characteristics in meningiomas: a cross-sectional study. *World Neurosurgery: X*, 12, 100111.
- Morrison, H., Sherman, L. S., Legg, J., Banine, F., Isacke, C., Haipek, C. A., ... &

- Herrlich, P. (2001). The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. *Genes & development, 15*(8), 968-980.
- Moussalem, C., Massaad, E., Minassian, G. B., Ftouni, L., Bsati, S., El Houshiemy, M. N., & Omeis, I. (2021). Meningioma genomics: a therapeutic challenge for clinicians. *Journal of Integrative Neuroscience, 20*(2), 463-469.
- Mubeen, B., Makhdoomi, R., Nayil, K., Rafiq, D., Kirmani, A., Salim, O & Ramzan, A. (2019). Clinicopathological characteristics of meningiomas: experience from a tertiary care hospital in the Kashmir Valley. *Asian Journal of Neurosurgery, 14*(01), 41-46.
- Mukhopadhyay, M., Das, C., Kumari, M., Sen, A., Mukhopadhyay, B., & Mukhopadhyay, B. (2017). Spectrum of meningioma with special reference to prognostic utility of ER, PR and Ki67 expression. *Journal of laboratory physicians, 9*(04), 308-313.
- Nagahama, A., Yashiro, M., Miki, Y., Morisako, H., Uda, T., Goto, T., & Ohata, K. (2019). p53 expression is a useful predictive marker for recurrence of meningioma. *Cancer Research, 79*(13\_Supplement), 4901-4901.
- Nag, S., Qin, J., Srivenugopal, K. S., Wang, M., & Zhang, R. (2013). The MDM2- p53 pathway revisited. *Journal of biomedical research, 27*(4), 254.
- Narla, S., Uppin, M. S., Saradhi, M. V., Sahu, B. P., Purohit, A. K., & Sundaram, C. (2014). Assessment of expression of epidermal growth factor receptor and p53 in meningiomas. *Neurology India, 62*(1), 37.
- Olar, A., Wani, K. M., Wilson, C. D., Zadeh, G., DeMonte, F., Jones, D. & Aldape, K. D. (2017). Global epigenetic profiling identifies methylation subgroups associated with recurrence-free survival in meningioma. *Acta neuropathologica, 133*, 431-444.
- Olar, A., Goodman, L. D., Wani, K. M., Boehling, N. S., Sharma, D. S., Mody, R. & Sulman, E. P. (2018). A gene expression signature predicts recurrence-free survival in meningioma. *Oncotarget, 9*(22), 16087.
- Omulecka, A., Papierz, W., Nawrocka-Kunecka, A., & Lewy-Trenda, I. (2006). Immunohistochemical expression of progesterone and estrogen receptors in meningiomas. *Folia Neuropathologica, 44*(2), 111-115.
- Ongaratti, B. R., Silva, C. B. O., Trott, G., Haag, T., Leães, C. G. S., Ferreira, N. P., & Pereira-Lima, J. F. S. (2016). Expression of merlin, NDRG2, ERBB2, and c-MYC in meningiomas: relationship with tumor grade and recurrence. *Brazilian Journal of Medical and Biological Research, 49*.
- Pachow, D., Andrae, N., Kliese, N., Angenstein, F., Stork, O., Wilisch-Neumann, & Mawrin, C. (2013). mTORC1 inhibitors suppress meningioma growth in mouse models. *Clinical Cancer Research, 19*(5), 1180-1189.
- Paramasivam, N., Hübschmann, D., Toprak, U. H., Ishaque, N., Neidert, M., Schrimpf, & Sahm, F. (2019). Mutational patterns and regulatory networks in epigenetic subgroups of meningioma. *Acta neuropathologica, 138*, 295-308.
- Parish, J., Shields, M., Jones, M., Wait, S., Lang, F., Macdonald, & Schramm, J. (2020). Proptosis, orbital pain, and long-standing monocular vision loss resolved by surgical resection of intraosseous speno-orbital meningioma: a



- case report and literature review. *Journal of Neurological Surgery Reports*, 81(01), e28-e32.
- Pavelin, S., Becic, K., Forempoher, G., Mrklic, I., Pogorelic, Z., Titlic, M., & Andelinovic, S. (2013). Expression of Ki-67 and p53 in meningiomas. *Neoplasma*, 60(5), 480-5.
- Pavelin, S., Becic, K., Forempoher, G., Tomic, S., Capkun, V., Drmic-Hofman, I., ... & Pogorelic, Z. (2014). The significance of immunohistochemical expression of merlin, Ki-67, and p53 in meningiomas. *Applied Immunohistochemistry & Molecular Morphology*, 22(1), 46-49.
- Pawloski, J. A., Fadel, H. A., Huang, Y. W., & Lee, I. Y. (2021). Genomic biomarkers of meningioma: a focused review. *International Journal of Molecular Sciences*, 22(19), 10222.
- Perry, A., Cai, D. X., Scheithauer, B. W., Swanson, P. E., Lohse, C. M., Newsham, I. F., & Gutmann, D. H. (2000). Merlin, DAL-1, and progesterone receptor expression in clinicopathologic subsets of meningioma: a correlative immunohistochemical study of 175 cases. *Journal of Neuropathology & Experimental Neurology*, 59(10), 872-879.
- Pham, M. H., Zada, G., Mosich, G. M., Chen, T. C., Giannotta, S. L., Wang, K., & Mack, W. J. (2011). Molecular genetics of meningiomas: a systematic review of the current literature and potential basis for future treatment paradigms. *Neurosurgical Focus*, 30(5), E7.
- Phillips, L. E., Koepsell, T. D., van Belle, G. A., Kukull, W. A., Gehrels, J. A., & Longstreth, W. T. (2002). History of head trauma and risk of intracranial meningioma: population-based case-control study. *Neurology*, 58(12), 1849-1852.
- Poniman, J., Cangara, M. H., Kaelan, C., Miskad, U. A., Arsyadi, G., Ghaznawe, M., & Rosyidi, R. M. (2020). Progesterone receptor expression and score differences in determining grade and subtype of meningioma. *Journal of Neurosciences in Rural Practice*, 11(04), 552-557.
- Qi, Z. Y., Shao, C., Huang, Y. L., Hui, G. Z., Zhou, Y. X., & Wang, Z. (2013). Reproductive and exogenous hormone factors in relation to risk of meningioma in women: a meta-analysis. *PloS one*, 8(12), e83261..
- Ragel, B. T., & Jensen, R. L. (2010). Aberrant signaling pathways in meningiomas. *Journal of neuro-oncology*, 99, 315-324.
- Rao, S., Sadiya, N., Doraiswami, S., & Prathiba, D. (2009). Characterization of morphologically benign biologically aggressive meningiomas. *Neurology India*, 57(6), 744..
- Riemenschneider, M. J., Perry, A., & Reifenberger, G. (2006). Histological classification and molecular genetics of meningiomas. *The Lancet Neurology*, 5(12), 1045-1054.
- Rodríguez-Colón, G., Bratton, E. M., Serracino, H., Bennett, J. L., & Hink, E. M. (2017). Sphenoid wing meningioma with extraocular muscle involvement mimicking idiopathic orbital inflammation. *Ophthalmic Plastic and Reconstructive Surgery*, 33(3), S97-S99.
- Ruttledge, M. H., Sarrazin, J., Rangaratnam, S., Phelan, C. M., Twist, E., Merel, P.,

- & Rouleau, G. A. (1994). Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas. *Nature genetics*, 6(2), 180-184.
- Santarsieri, M., Niyonkuru, C., McCullough, E. H., Dobos, J. A., Dixon, C. E., Berga, S. L., & Wagner, A. K. (2014). Cerebrospinal fluid cortisol and progesterone profiles and outcomes prognostication after severe traumatic brain injury. *Journal of neurotrauma*, 31(8), 699-712.
- Sahm, F. *et al.* (2021) *WHO Classification of Tumors. 5th Edition Central nervous system tumours*. 5th edn. Edited by L. DN. Lyon: International Agency for Research on Cancer.
- Saraf, Saraf, S., McCarthy, B. J., & Villano, J. L. (2011). Update on meningiomas. *The oncologist*, 16(11), 1604-1613.
- Sato, T., & Sekido, Y. (2018). NF2/Merlin inactivation and potential therapeutic targets in mesothelioma. *International journal of molecular sciences*, 19(4), 988.
- Scarpin, K. M., Graham, J. D., Mote, P. A., & Clarke, C. L. (2009). Progesterone action in human tissues: regulation by progesterone receptor (PR) isoform expression, nuclear positioning and coregulator expression. *Nuclear receptor signaling*, 7(1), nrs-07009.
- Shanthi, V., Grandhi, B., Rao, N. M., Rao, B. S., & Reddy, V. M. (2017). Assessing the prognostic importance of ER, PR expression in meningiomas by comparing with proliferative rate using Ki67. *Indian J Pathol Res Pract*, 6(2), 431-434.
- Schneider, B., Pülhorn, H., Röhrig, B., & Rainov, N. G. (2005). Predisposing conditions and risk factors for development of symptomatic meningioma in adults. *Cancer detection and prevention*, 29(5), 440-447.
- Schneider, M., Potthoff, A. L., Borger, V., Hadjiathanasiou, A., Schäfer, N., Güresir, & Schuss, P. (2020). Outcome of tumor-associated proptosis in patients with spheno-orbital meningioma: single-center experience and systematic review of the literature. *Frontiers in Oncology*, 10, 574074.
- Seliger, C., Meier, C. R., Becker, C., Jick, S. S., Proescholdt, M., Bogdahn, U & Leitzmann, M. F. (2017). Diabetes, use of metformin, and the risk of meningioma. *PloS one*, 12(7), e0181089.
- Seliger, C., Meier, C. R., Becker, C., Jick, S. S., Proescholdt, M., Bogdahn, U., ... & Leitzmann, M. F. (2017). Metabolic syndrome in relation to risk of meningioma. *Oncotarget*, 8(2), 2284.
- Shafat, M., Makhdoomi, R. and Walvir, N. (2023) 'Meningioma Prognostic Tool Based on Correlation of Histopathological Grading and Immunohistochemistry', *Oman Medical Journal*, (May 2022), pp. 3–9.
- Shibuya, M. (2015). Pathology and molecular genetics of meningioma: recent advances. *Neurologia medico-chirurgica*, 55(1), 14-27.
- Sievers, P., Hielscher, T., Schrimpf, D., Stichel, D., Reuss, D. E., Berghoff, A. S., ... & Sahm, F. (2020). CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas. *Acta neuropathologica*, 140, 409-413.
- Skiriute, D., Tamasauskas, S., Asmoniene, V., Saferis, V., Skauminas, K., Deltuva, V., & Tamasauskas, A. (2011). Tumor grade-related NDRG2 gene expression

- in primary and recurrent intracranial meningiomas. *Journal of neuro-oncology*, 102, 89-94.
- Slentz, D. H., Bellur, S., Taheri, M. R., Almira-Suarez, M. I., Sherman, J. H., & Mansour, T. N. (2018). Orbital malignant meningioma: a unique presentation of a rare entity. *Orbit*, 37(6), 457-462.
- Sughrue, M. E., Sanai, N., Shangari, G., Parsa, A. T., Berger, M. S., & McDermott, M. W. (2010). Outcome and survival following primary and repeat surgery for World Health Organization Grade III meningiomas. *Journal of neurosurgery*, 113(2), 202-209..
- Supartoto, A., Mahayana, I. T., Heriyanto, D. S., Sasongko, M. B., Respatika, H. D., Sakti, D. & Haryana, S. M. (2019). Neurofibromatosis type 2 gene mutation and progesterone receptor messenger RNA expression in the pathogenesis of sporadic orbitocranial meningioma. *International Journal of Ophthalmology*, 12(4), 571.
- Supartoto, A., Sasongko, M. B., Respatika, D., Mahayana, I. T., Pawiroranu, S., Kusnanto, H., ... & Haryana, S. M. (2019). Relationships between neurofibromatosis-2, progesterone receptor expression, the use of exogenous progesterone, and risk of orbitocranial meningioma in females. *Frontiers in oncology*, 8, 651.
- Supartoto, A., Mahayana, I. T., Christine, R. N., Suhardjo, S., Agni, A. N., & Sasongko, M. B. (2016). Exposure to exogenous female sex hormones is associated with increased risk of orbito-cranial meningioma in females: a case- control study. *International Journal of Ophthalmic Pathology*, 5(3), 1-6.
- Suppiah, S., Nassiri, F., Bi, W. L., Dunn, I. F., Hanemann, C. O., Horbinski, C. M., & Zadeh, G. (2019). Molecular and translational advances in meningiomas. *Neuro-oncology*, 21(Supplement\_1), i4-i17.
- Shayanfar, N., Mashayekhi, M., & Mohammadpour, M. (2010). Expression of progesterone receptor and proliferative marker ki 67 in various grades of meningioma.
- Tahir, M., Atif, T., Sohail, S., Nawazish, A., & Mushtaq, H. (2019). The Expression of Progesterone Receptors in Meningiomas of Different Grades. *Journal of Islamabad Medical & Dental College*, 8(2), 65-69.
- Telugu, R. B., Chowhan, A. K., Rukmangadha, N., Patnayak, R., Phaneendra, B. V., Prasad, B. C. M., & Reddy, M. K. (2016). Histopathological and immunohistochemical evaluation of meningiomas with reference to proliferative markers p53 and Ki-67. *Journal of clinical and diagnostic research: JCDR*, 10(1), EC15.
- Teranishi, Y., Okano, A., Miyawaki, S., Ohara, K., Ishigami, D., Hongo, H., & Saito, N. (2022). Clinical significance of NF2 alteration in grade I meningiomas revisited; prognostic impact integrated with extent of resection, tumour location, and Ki-67 index. *Acta Neuropathologica Communications*, 10(1), 1-13.
- Terzi, A., Saglam, E. A., Barak, A., & Soylemezoglu, F. (2008). The significance of immunohistochemical expression of Ki-67, p53, p21, and p16 in meningiomas tissue arrays. *Pathology-Research and Practice*, 204(5), 305-314.

- Toopalli, K., Vallury, S., Pandharpurkar, M., & Ather, M. (2015). Intraorbital meningiomas: A histopathologic study. *Scholars J Appl Med Sci*, 3(2B), 623-6.
- Trott, G., Pereira-Lima, J. F. S., Leães, C. G. S., Ferreira, N. P., Barbosa-Coutinho, L. M., & Oliveira, M. C. (2015). Abundant immunohistochemical expression of dopamine D 2 receptor and p53 protein in meningiomas: Follow-up, relation to gender, age, tumor grade, and recurrence. *Brazilian Journal of Medical and Biological Research*, 48, 415-419.
- Vasudevan, H. N., Braunstein, S. E., Phillips, J. J., Pekmezci, M., Tomlin, B. A., Wu, & Raleigh, D. R. (2018). Comprehensive molecular profiling identifies FOXM1 as a key transcription factor for meningioma proliferation. *Cell reports*, 22(13), 3672-3683.
- Wahab, M., & Al-Azzawi, F. (2003). Meningioma and hormonal influences. *Climacteric*, 6(4), 285-292.
- Wahyuhadi, J., Heryani, D., & Basuki, H. (2018). Risk of meningioma associated with exposure of hormonal contraception. A case control study. *Majalah Obstetri & Ginekologi*, 26(1), 36-41.
- Wang, B., Cui, Z., Zhong, Z., Sun, Y., Yang, G. Y., Sun, Q., & Bian, L. (2016). The role and regulatory mechanism of IL- 1 $\beta$  on the methylation of the NF2 gene in benign meningiomas and leptomeninges. *Molecular carcinogenesis*, 55(12), 2268-2277.
- Wiemels, J., Wrensch, M., & Claus, E. B. (2010). Epidemiology and etiology of meningioma. *Journal of neuro-oncology*, 99, 307-314.
- Wolfsberger, S., Doostkam, S., Boecher-Schwarz, H. G., Roessler, K., van Trotsenburg, M., Hainfellner, J. A., & Knosp, E. (2004). Progesterone-receptor index in meningiomas: correlation with clinico-pathological parameters and review of the literature. *Neurosurgical review*, 27, 238-245.
- Zador, Z., Landry, A. P., Haibe-Kains, B., & Cusimano, M. D. (2020). Meta-gene markers predict meningioma recurrence with high accuracy. *Scientific Reports*, 10(1), 18028.
- Zhang, W., & Xu, J. (2017). DNA methyltransferases and their roles in tumorigenesis. *Biomarker research*, 5(1), 1-8.